The FDA has notified healthcare professionals of an update to a previous alert from September 2007 addressing the interaction of ceftriaxone with calcium-containing products.  At the FDA’s request, Roche, which manufactures Rocephin (ceftriaxone sodium injection), has conducted two in vitro studies to assess the potential for precipitation of ceftriaxone-calcium when these products are mixed in vials and infusion lines as well as in neonatal and adult plasma. Based on results from these studies, the FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients ≥28 days of age, using the precautionary recommendations noted. For all age groups, the FDA is no longer recommending that ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

For more information visit